| 1 |
33444079 | Subcutaneous Rituximab-MiniCHOP Compared With Subcutaneous Rituximab-MiniCHOP Plus Lenalidomide in Diffuse Large B-Cell Lymphoma for Patients Age 80 Years or Older. | 2021 Apr 10 |
1 |
| 2 |
33555941 | Addition of Lenalidomide to R-CHOP Improves Outcomes in Newly Diagnosed Diffuse Large B-Cell Lymphoma in a Randomized Phase II US Intergroup Study ECOG-ACRIN E1412. | 2021 Apr 20 |
1 |
| 3 |
33621109 | ROBUST: A Phase III Study of Lenalidomide Plus R-CHOP Versus Placebo Plus R-CHOP in Previously Untreated Patients With ABC-Type Diffuse Large B-Cell Lymphoma. | 2021 Apr 20 |
1 |
| 4 |
33989279 | Lenalidomide in DLBCL: are we past the cell of origin? | 2021 May |
1 |
| 5 |
31702836 | Lenalidomide maintenance for diffuse large B-cell lymphoma patients responding to R-CHOP: quality of life, dosing, and safety results from the randomised controlled REMARC study. | 2020 Apr |
1 |
| 6 |
29946110 | CNS relapse in patients with DLBCL treated with lenalidomide plus R-CHOP (R2CHOP): analysis from two phase 2 studies. | 2018 Jun 26 |
1 |
| 7 |
28426350 | Lenalidomide Maintenance Compared With Placebo in Responding Elderly Patients With Diffuse Large B-Cell Lymphoma Treated With First-Line Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone. | 2017 Aug 1 |
1 |
| 8 |
29212067 | Lenalidomide Maintenance after R-CHOP Therapy in Diffuse Large B-Cell Lymphoma: Can It Be a Standard of Care. | 2017 |
1 |
| 9 |
27089170 | ROBUST: Lenalidomide-R-CHOP versus placebo-R-CHOP in previously untreated ABC-type diffuse large B-cell lymphoma. | 2016 Jul |
3 |
| 10 |
24706190 | Suitable drug combination with bortezomib for multiple myeloma under stroma-free conditions and in contact with fibronectin or bone marrow stromal cells. | 2014 Jun |
1 |
| 11 |
22792112 | Lenalidomide in diffuse large B-cell lymphomas. | 2012 |
1 |